Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Hematologic Neoplasms

Hypersensitivity

Lymphoproliferative Disorders

Myeloproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Bone Marrow Diseases

Hematologic Diseases

Chronic Myeloproliferative Disorders

Fibrinolytic Agents

Anticoagulants

All Drugs and Chemicals

Heparin

Calcium heparin

Immunosuppressive Agents

Patients followed in the haematology unit of Hospices Civils de Lyon for lymproliferative disorders as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) .

Patients followed in the medicine of aging unit in the Hospices Civils de Lyon without haematological malignancies, without chemotherapy and without immunosuppressive treatment (≤ 5 years)

Patients followed in the haematology unit of Hospices Civils de Lyon for myeloproliferative disorders as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).

The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.

Blood collection for the evaluation of the anti-drugs sensitivity

Charles Pr DUMONTET, PhD, MD

Marc Pr BONNEFOY, MD

Charles DUMONTET, MD

Marc BONNEFOY, MD

Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)) .

Over the last decade, the treatments have evolved significantly but the overall survival remains limited, especially for the AML and MM patients. There's an ongoing imperative to continue in-vitro and in-vivo studies to better evaluate the anti-cancer drugs sensitivity and therefore improving the response to treatments and open new fields of application. The healthy control group will be contributing to produce some pertinent and significant data for the results of the index cases group.

The investigators aim to analyze 10 differents drugs, common use in chemotherapy or immunotherapy and evaluate by 2 ways the sensitivity: first, Flow cytometry (cells apoptosis by Annexine V and propidium iodide) on fresh samples and in a second time, monitoring of the blasts in the mouse's blood after injection.

In Vitro Drug Sensitivity Testing of Fresh Human Samples

Evaluation of Anti-cancer Drugs Sensitivity on Fresh Samples From Healthy Patients and Patients With Myeloproliferative or Lymphoproliferative Disorders

Sensitivity determined by in-vitro

* Tumor cells mortality by Flow cytometry
* Monitoring of the blasts in the mouse's blood after injection

Sensitivity determined by in-vivo fresh samples:

Hospices Civils de Lyon

Nutritional and Metabolic Diseases

Substance Related Disorders

Symptoms and General Pathology

Wounds and Injuries

Heart Failure

Vascular Diseases

Metabolic Diseases

Heart Diseases

Drug-Related Side Effects and Adverse Reactions

Cardiotoxicity

Chemically-Induced Disorders

Radiation Injuries

Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects

Anti-Cancer Agents

Joe-Elie Salem, MD, PhD

Stéphane Edehry, MD

Edehry Stephane, MD

Joe-Elie Salem, Md, PhD

Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).

Several anticancer and supportive care drugs used in oncology have an impact on the cardiovascular and metabolic systems, leading to a wide range of cardiovascular and metabolic disorders and side effects. Those are poorly described, due to the evolution of the anticancer pharmacopeia, and recent recognition of these adverse events. This study will investigate the potential benefits of a specialized cardio-oncology check-up and follow-up in this context.

Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

Groupe Hospitalier Pitie-Salpetriere

Assistant director, clinical investigation center Paris Est

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
In Vitro Drug Sensitivity Testing of Fresh Human Samples	NCT05001386	Myeloproliferat... Lymphoprolifera...	Blood collectio...	18 Years -	Hospices Civils de Lyon
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care	NCT03882580	Cardiovascular ... Cardiovascular ... Cardiac Complic... Oncologic Compl... Cardiac Insuffi... Metabolic Disor... Vascular Disord... Cardiac Disorde...	Anti-Cancer Age...	18 Years -	Groupe Hospitalier Pitie-Salpetriere
In Vitro Drug Sensitivity Testing of Fresh Human Samples	NCT05001386	Myeloproliferat... Lymphoprolifera...	Blood collectio...	18 Years -	Hospices Civils de Lyon
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care	NCT03882580	Cardiovascular ... Cardiovascular ... Cardiac Complic... Oncologic Compl... Cardiac Insuffi... Metabolic Disor... Vascular Disord... Cardiac Disorde...	Anti-Cancer Age...	18 Years -	Groupe Hospitalier Pitie-Salpetriere

Spots Global Cancer Trial Database for anticancer drugs